6/17/21

PhaseBio Announces European Licensing Agreement with Alfasigma S.p.A for Commercialization of Bentracimab

6/15/21

Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

5/12/21

ALSS Secures $7M Series B Funding To Commercialize Novel Vaccine Delivery System For Poultry Industry

5/11/21

Mindera Raises Over $12M Series A-2 Financing

4/30/21

BILLION-DOLLAR RANCH HANDS: How Silicon Ranch became a homegrown powerhouse

4/27/21

Castle Biosciences Signs Definitive Agreement to Acquire Myriad myPath® Laboratory

3/2/21

G1 Therapeutics and Boehringer Ingelheim Announce Commercial Availability of COSELA™ (trilaciclib), the Only FDA-Approved Multilineage Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression

2/12/21

FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression

12/22/20

The 21 Best Stocks to Buy for 2021

12/18/20

Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

12/15/20

Silicon Ranch Closes $225 Million Equity Raise with Existing Shareholders

12/9/20

G1 Therapeutics Presents Final Phase 2 Clinical Data on Trilaciclib in Combination with Chemotherapy in Metastatic Triple-Negative Breast Cancer Demonstrating Significant Improvement in Overall Survival at 2020 San Antonio Breast Cancer Symposium

11/2/20

Castle Biosciences Announces Commercial Launch of DecisionDx DiffDx-Melanoma

10/8/20

Castle Biosciences Announces Expanded Medicare Coverage for DecisionDx-Melanoma in Cutaneous Melanoma

10/6/20

PhaseBio Doses First Patients in Canada as Part of the REVERSE-IT Global Phase 3 Trial of Bentracimab

9/2/20

Castle Biosciences Announces Commercial Launch of DecisionDx-SCC

7/27/20

Mindera Corporation Announces Appointment of George W. Mahaffey as President and Chief Executive Officer

6/24/20

Castle Biosciences Announces Pricing of $74.0 Million Public Offering of Common Stock

5/27/20

PhaseBio Launches Clinical Trial to Evaluate PB1046 as a Treatment for Hospitalized COVID-19 Patients

4/13/20

Orig3n Receives FDA Emergency Use Authorization (EUA) For Coronavirus 2019 Test

1/13/20

PhaseBio Announces Acquisition of Novel Oral Aldosterone Synthase Inhibitor to Develop for Treatment-Resistant Hypertension

1/10/20

PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals® forPB2452

11/21/19

AN2 Therapeutics Launches with $12 Million in Series A Funding and Announces a Strategic Partnership with Brii Biosciences

11/19/19

Silicon Ranch signs on for 107-MW solar project for Facebook in Georgia

10/29/19

Castle Biosciences Presents Clinical Validation Study for its Cutaneous Squamous Cell Carcinoma Prognostic Test at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting

10/15/19

PhaseBio Announces First Patient Dosed in Phase 2b Clinical Trial of PB2452 for Reversal of the Antiplatelet Activity of Ticagrelor

10/7/19

Newly Published Systematic Review Confirms Strength of Evidence and Outlines Appropriate Use Criteria for Integration of DecisionDx-Melanoma in Management of Patients with Cutaneous Melanoma

9/4/19

REGENXBIO Announces Exclusive Worldwide Option and License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314

8/14/19

PhaseBio Announces Receipt of Minutes of End-of-Phase 1 Meeting with the FDA and Alignment on a Single, Non-Randomized Phase 3 Trial to Support BLA Submission for PB2452

7/29/19

Castle Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

6/26/19

Silicon Ranch Launches Regenerative Energy™

6/18/19

G1 THERAPEUTICS ANNOUNCES UPDATED RESULTS FROM PHASE 2 TRIAL OF TRILACICLIB IN COMBINATION WITH CHEMOTHERAPY SHOWED STATISTICALLY SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL IN WOMEN WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER

6/17/19

PhaseBio Announces Positive Preliminary Results from Phase 2a Clinical Trial of PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor in Older and Elderly Subjects

4/29/19

G1 Therapeutics Announces Positive Feedback from Trilaciclib End-of-Phase 2 Meeting with FDA; Expects to File NDA in 2020

4/8/19

PhaseBio Announces Closing of Public Offering of Common Stock

4/8/19

PhaseBio Receives Breakthrough Therapy Designation

3/19/19

Applied LifeSciences & Systems Announces Closing of its $8 Million Series A Round of Equity Financing

3/17/19

Full Results from PhaseBio Phase I Clinical Trial Published in New England Journal of Medicine

3/6/19

Publication of Independent Prospective, Multicenter Study Reinforces Accuracy of DecisionDx-Melanoma Test Recurrence Risk Prediction

2/20/19

Clearside Receives Notification of FDA Acceptance of NDA Filing for XIPERE

2/7/19

Newly Published Study Shows DecisionDx-Melanoma Prognostic Test Accurately Identified Risk for Patients with Melanoma of the Head and Neck

1/30/19

Castle Biosciences Announces Publication of Prospective Multicenter Study Demonstrating that its DecisionDx-Melanoma Test can Inform Sentinel Lymph Node Biopsy Decisions

1/7/19

Castle Biosciences’ DecisionDx-Melanoma Test Identifies High-Risk Melanoma Patients Among Those Traditionally Staged as Low Risk in Newly Published Study

12/6/18

Castle Biosciences Announces the Appointment of Genomic Health CFO G. Bradley Cole to its Board of Directors

12/5/18

Silicon Ranch to Help Power Facebook Data Center in Georgia

10/18/18

Castle Biosciences Announces Medicare Coverage for the DecisionDx-Melanoma Test in Cutaneous Melanoma

8/27/18

PhaseBio Secures $34 Million in Series D Financing

7/30/18

Castle Biosciences Presents Data Demonstrating the DecisionDx-Melanoma Test Improved AJCC-Based Risk Prediction for Melanoma Recurrence and Metastasis

6/28/18

APPELLO COMPLETES $10.5 MILLION SERIES A FINANCING LED BY DEERFIELD MANAGEMENT AND MOUNTAIN GROUP PARTNERS

5/31/18

Clearside Biomedical Announces Positive Topline Results from Phase 2 Clinical Trial of CLS-TA Used with Eylea in Patients with Diabetic Macular Edema

5/23/18

Anthem, Inc. to Acquire Aspire Health

4/16/18

G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer

3/28/18

Castle Biosciences Announces Inclusion of DecisionDx-UM Prognostic Test in New NCCN Guidelines for Uveal Melanoma

3/15/18

G1 Therapeutics Announces Positive Trilaciclib Phase 2a Topline Data Showing Robust Myelopreservation Bene ts in Patients with Small Cell Lung Cancer

3/5/18

Clearside Biomedical Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of CLS-TA in Macular Edema Associated with Non-Infectious Uveitis

1/22/18

Shell Takes a Major Stake in US Solar Developer Silicon Ranch

1/22/18

Shell Acquires Interest in Silicon Ranch Corporation

1/4/18

AgTech Accelerator Launches First Investment in Novel Fungicide Company, Boragen Inc., with $10 Million Series A Financing

1/4/18

AgTech Accelerator Makes First Animal Health Industry Investment in Skyline Vet Pharma with $5 Million Series A Financing

12/18/17

G1 Therapeutics Added to Nasdaq Biotechnology Index

9/18/17

G1 Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes

7/31/17

Myomo, Inc. Obtains CE Mark Approval for MyoPro®

7/13/17

G1 Therapeutics Appoints Sir Andrew Witty to Board of Directors

6/27/17

Biotech company ORIG3N nabs $20 mln

6/9/17

Myomo, Inc. Completes Historic Initial Public Offering

5/30/17

G1 Therapeutics to Present Clinical Data on CDK4/6 Inhibitor Trilaciclib at the 2017 American Society of Clinical Oncology Annual Meeting

5/25/17

FUTURE Local Coverage Determination for MolDX: DecisionDxUM (Uveal Melanoma) (L37033)

5/16/17

G1 Therapeutics Announces Pricing of Initial Public Offering

4/18/17

NeuroTronik Announces $23.1 Million Series B Preferred Stock Financing

3/29/17

G1 Therapeutics Announces Presentations at the 2017 American Association for Cancer Research Annual Meeting

1/10/17

G1 Therapeutics Initiates Three Drug Development Programs in Breast Cancer

12/5/16

G1 Therapeutics to Evaluate Trilaciclib (G1T28) in Combination with Immune Checkpoint Inhibitor in Small-Cell Lung Cancer

11/2/16

AgTech Accelerator Corporation Announces the Addition of Animal Health Pioneer Elanco to Blue-Chip Investor Syndicate; Completes $20 Million First Closing

9/21/16

NuSirt Biopharma and OWL Metabolomics Partner to Advance Treatment of NASH / Non-alcoholic Steatohepatitis

6/1/16

Clearside Biomedical, Inc. Announces Pricing of Initial Public Offering

5/11/16

G1 Therapeutics Secures $47 Million Series C Financing

4/27/16

Mississippi Power, Silicon Ranch break ground on new solar energy facility

4/27/16

Partners Group invests USD 100 million in Silicon Ranch Corporation, a US developer, owner and operator of solar power production facilities

4/26/16

Clearside Biomedical, Inc. Announces Positive Preliminary Phase 2 Results in Patients with Macular Edema Associated with Retinal Vein Occlusion

4/15/16

TVA and Silicon Ranch Partner on Large-Scale Solar Farm at NSA Mid-South

2/1/16

A Local Startup Is Building the World’s Largest iPS Stem Cell Bank

1/26/16

Clinical Trial Results Show Synergy between NuSirt Technology and Metformin in Patients with Type 2 Diabetes

12/14/15

Clearside Biomedical, Inc. Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space (SCS™) Drug Administration

12/10/15

NuSirt Biopharma Receives FDA Fast Track Designation for Non-Alcoholic Fatty Liver Disease Treatment

12/3/15

Clearside Biomedical, Inc. Completes $20 Million Series C Financing

12/1/15

Green Power EMC and Silicon Ranch Dedicate 20 MW Georgia Solar Facility

1/15/15

Clearside Biomedical, Inc. Initiates Phase 2 Clinical Trial For the Treatment of Macular Edema Associated With Non-Infectious Uveitis

7/7/14

NuSirt Biopharma Technology Presented at American Diabetes Association Scientific Sessions